Mara Kramer has 20 years of extensive experience from Site, Country, Regional and Global Level. Ms Kramer’s experience in the study coordination, site management, regulatory environment and global feasibility matters allows her to include several perspectives and innovative approaches on the process.She considers that Human and artificial intelligence are complement factors of success supporting the objectives and vision of Sanofi.

Ms Kramer holds a BA in Nutrition from Universidad Veracruzana, Mexico. Previous roles include: Deputy Head Global Feasibility and Competitive Intelligence, Global Feasibility Lead, Cluster Regulatory Manager, Site Manager and Study Coordinator.

Sylvie Kruyner is a Clinical Study Manager and Decentralized Clinical Trials (DCT) Advisor at Bayer. Bringing deep expertise in global clinical trial operations, she combines a passion for innovation with a customer-centric approach to advance patient-focused research.

She has accumulated over 15 years of experience managing complex trials within both CRO and sponsor settings across Europe and the US, and has been with Bayer since 2014. Sylvie has played a pioneering role in designing and implementing hybrid and fully virtual decentralized clinical trials, helping to transform traditional study frameworks.

She holds a Master’s degree in Health Care Management from Ghent University, Belgium, and currently lives in Overland Park, US.

_

Lovisa Afzelius is an origination partner at Flagship Pioneering. A computational scientist by training, she brings to Flagship two decades of leadership experience in emerging biotechs and large pharma companies, and a passion for data-driven drug discovery. Dr Afzelius has served as CEO, co-founder, president, board chairman and executive director in emerging biotech and large pharma companies. She joined Flagship in early 2020, leading innovation as co-founder and founding CEO of Alltrna, Apriori Bio, Metaphore Biotechnologies and Prologue Medicines. Before joining the Flagship ecosystem, Dr Afzelius built and led Pfizer’s systems immunology function and served as executive director of clinical programs. In 2017, she co-founded Elsa.science, a digital health company for which she serves on the board. Dr Afzelius began her career at AstraZeneca and has received numerous accolades for her work, including being named one of the 100 “most influential persons under 40 in Sweden” by the business magazine, Affärsvärlden. In 2022, Dr Afzelius, was named one of the 20 women blazing trails in biopharma Endpoints for her work with companies using AI and machine learning to advance drug development. In 2023, Apriori Bio was named a Technology Pioneer by the World Economic Forum and received an honorable mention for Fast Company’s World Changing Ideas list in the Rapid Response category. Apriori’s co-founder and CEO, including at Apriori. She holds a PhD in computational chemistry from Uppsala University, a Master of Science in integrative pharmacology from Gothenburg University as well as an MBA from MIT.

Vikram Agarwal completed his PhD in Dr David Bartel's lab at the Massachusetts Institute of Technology, where he utilized computational approaches to study the principles of microRNA targeting. He completed his post-doctoral research in Dr Jay Shendure's laboratory at the University of Washington, where he applied deep learning methods and massively parallel reporter assays to investigate the mechanisms of transcriptional gene regulation. Transitioning into industry, Vikram worked at Calico Life Sciences LLC, an Alphabet company whose mission is to better understand the mechanisms underlying human aging. There he applied deep learning methods with Dr David Kelley to better understand transcriptional and post-transcriptional gene regulation as well as its link to human genetics. He is currently the Head of mRNA Platform Design Data Science at the mRNA Center of Excellence at Sanofi, where his team is applying machine learning and deep learning methods towards the design of enhanced mRNA therapeutics.

Dr. Ali is Sr. Director of Scientific Affairs and Technical Marketing at Ascendia Pharma. He worked in the Pharma industry for over 30 years. His expertise includes synthesis and formulation of small molecules such as lipids and oncology drugs, liposomes and gene delivery, hot melt extrusion, spray drying among, self emulsifying drug delivery systems (SEDDS; SMEDDS).

Dr. Ali obtained his PhD in Chemistry from the City University of New York, NY, and continued his postdoctoral work in Physical Biochemistry and Biophysics at the University of Minnesota and Cornell University.  Dr. Ali served as a member of the editorial advisory board of several pharmaceutical journals. He is also the Editor-In-Chief of Journal of Analytical and Pharmaceutical Research. Dr. Ali is served as vice chair of the USP Council of Expert for Excipient Test Methods committee (2020-2025) and will continue as USP Council of Expert for Excipient Chapters in 2025-2030 cycle. Dr. Ali is the recipient of IPEC Foundation’s 2020 Henk de Jong industrial research award for his contributions to formulations and excipient technologies. He has published over 70 articles in scientific journals and is an inventor of several US and European patents. Dr. Ali is also an AAPS Fellow.

Shai Assia is a Product Development leader with more than 15 years of experience in a wide range of responsibilities and organizations. Shai leads the Medical Device Design, Development and Manufacturing for novel Combination Products and Drug-Delivery Platforms. Prior to Clexio Biosciences, Shai was the Head of Medical Devices at MobileODT, developing Optical Detection Technologies for early-stage cancer detection through enhanced visual assessment. Mr Assia holds a BSc in Bio-Medical Engineering from Tel Aviv University as well as a MSc in Mechanical Engineering and MBA from the Massachusetts Institute of Technology (MIT), where he received the Leaders for Global Operations Fellowship.

X

Dr Isabelle Aubert works as a Senior Scientist at Sunnybrook Research Institute, Professor and Co-Vice Chair of Wellness, Inclusion, Diversity, and Equity in the Department of Laboratory Medicine and Pathobiology at the Temerty Faculty of Medicine, University of Toronto. She holds a Tier 1 Canada Research Chair in Brain Repair and Regeneration, and she is an elected Fellow of the Canadian Academy of Health Sciences. She obtained her PhD in neurosciences, on brain plasticity in aging and neurodegenerative diseases, at McGill University in the Department of Neurology and Neurosurgery. As a Medical Research Council of Canada fellow, Dr Aubert completed her post-doctoral training on regenerative gene therapies for the brain at the Salk Institute for Biological Studies. Dr Aubert has over 30 years of expertise in regenerative gene therapies for the aging and diseased brain. At Sunnybrook, she leads the Brain Repair Group in evaluating the impact of focused ultrasound and blood-brain barrier modulation for the delivery of therapeutics to the brain, and on the plasticity of molecular, cellular and cognitive systems in animal models. Through collaborative work, Dr Aubert and team members are developing molecular, cellular and gene therapies that can halt neurodegeneration and promote regeneration, particularly when combined with magnetic resonance image-guided focused ultrasound in preclinical models of neurodegenerative disorders, specializing in Alzheimer’s disease.

Claire Authesserre, PhD, is an engineer graduated from ESPCI Paris and Imperial College of London where she obtained a MSc in Biomedical engineering in 2013. She then completed a PhD in microfluidics at CEA Leti in the Department of Microtechnologies for Healthcare and Biology. In 2017, Dr Authesserre joined EVEON as R&D Fluidics Manager, leading a team of fluidics engineers working closely with both the Mechanical and Digital teams, to design medical devices with optimized performances to fit with customer and patient needs. Since May 2022, Dr Authesserre has been Project Manager.

X

Manasi Baker, PhD, is a Senior Scientist in Secant Group’s Translational Product Development team which focuses on the development of the novel polymer platform, Hydralese®, for improved drug delivery applications. Dr Baker focuses on developing multiple long-acting Hydralese form types for both small and large molecule delivery, including microspheres, gastroretentive devices, and subcutaneous implants. She also manages the platform’s intellectual property and provides her polymer expertise to lead customer development projects to success. During her career, Dr Baker has specialized in preformulation and formulation development of various form factors spanning from drug delivery devices to home and personal care products. Dr Baker has a PhD in Pharmaceutics from Philadelphia College of Pharmacy, University of the Sciences, and a Bachelor of Pharmacy from the University of Mumbai.